Mechanisms of Inhibition of IL-6-Mediated Immunoglobulin Secretion by Dexamethasone and Suramin in Human Lymphoid and Myeloma Cell Lines

Leukemia and Lymphoma

Volumn 21, Issue 42067, 1996, Pages 293-303

  Shiao, Rei Tsang ^a   Mcleskey, Susan B ^a   Khera, Samira Y ^a   Wolfson, Amy ^a   Freter, Carl E ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

autocrine; Dexamethasone; gp130; IgM; IL 6; lymphoma; multiple myeloma; receptor; suramin

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M; IMMUNOGLOBULIN MU CHAIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; RECOMBINANT INTERLEUKIN 6; SURAMIN;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOGLOBULIN PRODUCTION; LYMPHOID CELL LINE; MYELOMA CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG INTERACTIONS; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; INTERLEUKIN-6; LYMPHOID TISSUE; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; RABBITS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; SECRETORY RATE; SURAMIN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0030009675     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199209067610     Document Type: Article

References (45)

1. Salmon S. E., Seligmann M. B-cell neoplasia in man. Lancet 1974; 2: 1230
2. Barlogie B., Epstein J., Selvanavagam P., Alexanian R. Plasma cell myeloma: New biological insights and advances in therapy. Blood 1989; 73: 865
3. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332: 83 – 85
4. Schwab G., Siegal C. B., Aarden L. A., Neckers L. M., Nordan R. Characterization of interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991; 77: 578 – 593
5. Klein B., Zhang X., Jourdan M., Cotent L., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989; 73: 517 – 526
6. Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med 1989; 170: 613 – 618
7. Zhang X-G., Bataille R'., Jourdan M., Saeland S., Banchereau J., Mannoni P., Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76: 2599 – 2605
8. Van Snick J. Interleukin-6: An overreview. Ann. Rev. Immunol 1990; 8: 253 – 278
9. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1 – 10
10. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol. Today 1990; 11: 443 – 49
11. Lotz M., Jirik F., Kabourdis P., Tsoukas C., Hirano T., Kishimoto T., Carson D. A. B cells stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J. Exp. Med 1988; 167: 1253 – 1258
12. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocytes-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci., USA 1987; 84: 7251 – 7255
13. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58: 573 – 581
14. Stahl N., Boulton T. G., Farruggella T., Ip N. Y., Davis S., Witthuhn B. A., Quelle F. W., Silvennoinen O., Barbieri G., Pellegrini S., Ihle J. N., Yancopoulos G. D. Association and activation of jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components. Science 1994; 263: 92 – 95
15. Murakami M., Hibi M., Nakagawa N., Nakagawa T., Yasukawa K., Yamanishi K., Taga T., Kishimoto T. IL-6-induced homodimerization of gp 130 and associated activation of a tyrosine kinase. Science 1993; 260: 1808 – 1810
16. Alexanian R., Haut A., Khan A. U. Treatment of multiple myeloma combination chemotherapy with different melphalan dose regimens. JAMA 1969; 298: 1680 – 1685
17. Alexanian R., Yap B. S., Body G. P. Prednisone pulse therapy for refectory multiple myeloma. Blood 1983; 62: 572 – 577
18. Sporn J. R., McIntyre R. O. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin. Oncol 1986; 13: 317 – 325
19. Buziad A. C., Durie B. G. M. Management of refractory myeloma: a review. J. Clin. Oncol 1988; 6: 889 – 905
20. Hawking F. Suramin: with special reference to onchocerciasis. Advances in pharmacology and chemotherapy, S. Garrattini. Academic Press, New York 1978; 289 – 322; 15
21. Stein C. A. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993; 53: 2239 – 2248
22. Levine A. M., Gill P. S., Cohen J., Hawkins L. G., Fomenti S. C., Aguilar P., Meyer P. R., Krailo M., Parker J., Rasheed S. Suramin antiviral therapy in the acquired immunodeficiency syndrome. Ann. Intern. Med 1986; 105: 32 – 37
23. Nakajima M., Dechavingy A., Johnson C. E., Hamada J., Stein C. A., Nicolson G. L. Suramin, a potent inhibitor of melanoma heparinase and invasion. J. Biol. Chem 1991; 266: 9661 – 9666
24. Gagliardi A., Hadd H., Collins D. C. Inhibition of angiogenesis by suramin. Cancer Res 1992; 52: 5073 – 5075
25. Shiao R., Miglietta L., Khera S. Y., Wolfson A., Freter C. E. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Leukemia & Lymphoma 1995; 17: 485 – 494
26. Yokoi T., Miyawaki A., Yachie K., Kato Y., Kasahara Y., Tanihuchi N. Epstein-Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor. Immunol 1990; 70: 100 – 105
27. Rigby P. W., Dieckmann M., Rhodes C., Berg P. Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J. Mol. Biol 1977; 113: 237 – 251
28. Brenner C. A., Tam A. W., Nelson P. A., Engleman E. G., Suzuki N., Fry K. E., Larrick J. W. Message amplification phenotyping (MAP Ping): A technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques 1989; 7: 1096 – 1103
29. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama S., Iwamatsu A., Tsunasawa S., Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73 – 76
30. Meyers F. J., Gumerlock P. H., Kawasaki E. S., Wang A. M., deVere White R. W., Erlich H. A. Bladder cancer: Human leukocyte antigen II, interleukin-6, and Interleukin-6 receptor expression determined by the polymerase chain reaction. Cancer 1991; 67: 2087 – 2095
31. Inoue K., Sugiyama H., Ogawa H., Yamagami T., Azuma T., Oka Y., Miwa H., Kita K., Hiraoka A., Masaoka T., Nasu K., Kyo T., Dohy H., Hara J., Kanamaru A., Kishimoto T. Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia. Blood 1994; 8: 2672 – 2680
32. Ballagi-Pordány A., Ballagi-Pordáany A., Funa K. Quantitative determination of mRNA phenotypes by the polymerase chain reaction. Anal. Biochem 1991; 196: 89 – 94
33. Becker S., Quay J., Soukup J. Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J. Immunol 1991; 147: 4307 – 4312
34. Zhang X. G., Klein B., Bataille R. Interleukin-6 is a potent myeloma cell growth factor in patient with aggressive multiple myeloma. Blood 1989; 74: 11 – 13
35. Gomi M., Moriwaki K., Katagiri S., Kurata Y., Thompson E. B. Glucocorticoid effects on myeloma cells in culture: Correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res 1990; 50: 1873 – 1878
36. Waage A., Slupphaug G., Shalaby R. Glucocorticoid inhibit the production of IL-6 from monocytes, endothial cells and fibroblasts. Eur. J. Immunol 1990; 20: 2439 – 2443
37. Ishikawa H., Tanaka H., Iwato K., Tanabe O., Asaoku H., Nobuyoshi M., Yamamoto I., Kawano M., Kuramoto A. Effects of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin-1β osteoclast activating factor-induced bone resorption. Blood 1990; 75: 715 – 720
38. Tobler A., Meier R., Seitz M., Dewald B., Baggiolini M., Fey M. F. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood 1992; 79: 45 – 51
39. Siegall C. B., Nordan R. P., Fitz Gerald D. J., Pastan I. Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL-6-PE40) on tumor cells. Mol. and Cell. Biol 1990; 10: 2443 – 2447
40. Kipps T. J., Carson D. A. Hematology, W. J. Williams, E. Beutler, A. Erslev, M. Lichtman. McGraw Hill. 1990; 932 – 938, In
41. Hensey C. E., Boscoboinik D., Azzi A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS letters 1989; 258: 156 – 158
42. Jindal H. K., Anderson C. W., Davis R. G., Vishwanatha J. K. Suramin affects DNA synthesis in Hela cells by inhibition of DNA polymerases. Cancer Res 1990; 50: 7754 – 7757
43. Bojanowski K., Lelievre S., Markovits J., Couprie J., Jacqueminsablon A., Larsen A. K. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcomacells. Proc. Natl. Acad. Sci. USA 1992; 89: 3025 – 3029
44. Baumann H., Strassmann G. Suramin inhibits the stimulation of acute phase plasma protein genes by IL-6-type cytokines in rat hepatoma cells. J. Immunol 1993; 151: 1456 – 1462
45. Strassmann G., Fong M., Freter C. E., Windsor S., D'Alessandro F., Nordan R. P. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26 mediated experimental cancer cachexia in vivo. J. Clin. Invest 1993; 92: 2152 – 2159